What is Leerink Partnrs’ Forecast for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Neurogene in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($1.12) per share for the quarter. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($4.76) EPS and FY2026 earnings at ($6.03) EPS.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.05. The business had revenue of $0.93 million during the quarter.

NGNE has been the subject of several other reports. William Blair reaffirmed an “outperform” rating on shares of Neurogene in a research report on Tuesday. HC Wainwright decreased their price objective on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $59.80.

Neurogene Trading Down 5.0 %

Shares of Neurogene stock opened at $15.33 on Thursday. The business’s fifty day simple moving average is $16.92 and its 200 day simple moving average is $28.96. Neurogene has a 12 month low of $13.47 and a 12 month high of $74.49. The firm has a market capitalization of $227.73 million, a P/E ratio of -3.59 and a beta of 1.01.

Institutional Trading of Neurogene

Institutional investors have recently modified their holdings of the business. Casdin Capital LLC raised its holdings in Neurogene by 146.9% during the 4th quarter. Casdin Capital LLC now owns 1,295,361 shares of the company’s stock valued at $29,612,000 after acquiring an additional 770,745 shares during the period. FMR LLC grew its position in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after purchasing an additional 659,515 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Neurogene by 10,395.3% during the 4th quarter. JPMorgan Chase & Co. now owns 481,001 shares of the company’s stock valued at $10,996,000 after purchasing an additional 476,418 shares during the period. Samsara BioCapital LLC raised its stake in shares of Neurogene by 35.4% during the 4th quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company’s stock valued at $39,254,000 after purchasing an additional 449,337 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new stake in Neurogene during the 4th quarter worth about $10,245,000. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the transaction, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 9.92% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.